Dewey Kim

Directorate-General for Interpretation — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index2.6kcitations115works54.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(46), Advanced Breast Cancer Therapies(46), Cancer Treatment and Pharmacology(39), Breast Cancer Treatment Studies(34), Lung Cancer Treatments and Mutations(16)

Publications114 total

The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries
2023· 20 citedOpen Access
Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab
JCO Precision Oncology·2023· 5 cited
A genomic score to predict local control among patients with brain metastases managed with radiation.
Journal of Clinical Oncology·2023
A genomic score to predict local control among patients with brain metastases managed with radiation
Neuro-Oncology·2023· 7 citedOpen Access
Supplemental Table 6 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 1 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Data from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023· 1 citedOpen Access
Supplemental Table 1 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 2 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 2 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Figure 8 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 5 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 8 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 3 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Figure 4 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Figure 5 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Figure 4 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Figure 9 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 4 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
Supplemental Table 7 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Nikhil Wagle(35), Ofir Cohen(21), Adrienne G. Waks(21), Nancy U. Lin(18), Seth A. Wander(17), Karla Helvie(17), Eric P. Winer(17), Jorge E. Buendia-Buendia(16), Sara M. Tolaney(15), Pingping Mao(14), Utthara Nayar(14), Esha Jain(14), Gabriela N. Johnson(13), Maxwell R. Lloyd(13), Flora Luo(13), Kailey J. Kowalski(13), Levi A. Garraway(13), Xueqian Gong(12), Stephen H. Parsons(12), Lacey M. Litchfield(12)